|
End-of-day quote
Shenzhen S.E.
30/10/2026
|
5-day change | 1st Jan Change | ||
| 4.340 CNY | +0.23% |
|
-3.34% | -16.86% |
Company Valuation: Northeast Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 6,848 | 8,384 | 9,051 | 7,646 | 7,531 | 7,449 |
| Change | - | 22.43% | 7.95% | -15.52% | -1.5% | -1.09% |
| Enterprise Value (EV) 1 | 7,967 | 8,322 | 7,403 | 4,178 | 4,656 | 5,959 |
| Change | - | 4.45% | -11.04% | -43.57% | 11.44% | 27.99% |
| P/E | 507x | 88.9x | 25.2x | 21.4x | 18.2x | 29x |
| PBR | 1.72x | 2.02x | 1.99x | 1.53x | 1.42x | 1.35x |
| PEG | - | 0x | 0x | - | 1.1x | -0.8x |
| Capitalization / Revenue | 0.93x | 1.03x | 1.03x | 0.93x | 1x | 1.05x |
| EV / Revenue | 1.08x | 1.02x | 0.84x | 0.51x | 0.62x | 0.84x |
| EV / EBITDA | 11.6x | 11.6x | 9.9x | 4.62x | 4.57x | 7.76x |
| EV / EBIT | 37.3x | 39.5x | 33.7x | 11.4x | 9.78x | 23.1x |
| EV / FCF | 21.7x | 6.29x | 6.2x | 2.52x | -20.7x | -4.81x |
| FCF Yield | 4.6% | 15.9% | 16.1% | 39.7% | -4.84% | -20.8% |
| Dividend per Share 2 | 0.008 | 0.014 | 0.1 | 0.1 | 0.1 | 0.055 |
| Rate of return | 0.16% | 0.23% | 1.58% | 1.87% | 1.9% | 1.05% |
| EPS 2 | 0.01 | 0.07 | 0.25 | 0.25 | 0.29 | 0.18 |
| Distribution rate | 80% | 20% | 40% | 40% | 34.5% | 30.6% |
| Net sales 1 | 7,384 | 8,145 | 8,809 | 8,243 | 7,503 | 7,075 |
| EBITDA 1 | 688.6 | 715.8 | 747.7 | 904.6 | 1,019 | 767.9 |
| EBIT 1 | 213.6 | 210.6 | 219.6 | 366.2 | 476 | 258.2 |
| Net income 1 | 12.26 | 99.03 | 350.1 | 358.5 | 409.8 | 260.1 |
| Net Debt 1 | 1,119 | -62.17 | -1,647 | -3,468 | -2,876 | -1,491 |
| Reference price 2 | 5.070 | 6.220 | 6.310 | 5.350 | 5.270 | 5.220 |
| Nbr of stocks (in thousands) | 1,350,702 | 1,347,873 | 1,434,316 | 1,429,103 | 1,429,103 | 1,427,088 |
| Announcement Date | 16/03/21 | 30/03/22 | 29/03/23 | 29/03/24 | 02/04/25 | 02/04/26 |
1CNY in Million2CNY
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 930M | ||
| 41.54x | 14.06x | 31.11x | 0.48% | 1,263B | ||
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | ||
| 38.61x | 8.62x | 17.83x | 2.33% | 521B | ||
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | ||
| 109.15x | 6.06x | 25.73x | 2.28% | 369B | ||
| 23.19x | 5.97x | 14.41x | 2.71% | 307B | ||
| 24.47x | 4.9x | 13.63x | 1.77% | 290B | ||
| 29.56x | 7.53x | 13.48x | 2.16% | 252B | ||
| -49.1x | 7.47x | 29.35x | 1.93% | 212B | ||
| Average | 31.02x | 7.40x | 19.73x | 2.01% | 426.29B | |
| Weighted average by Cap. | 37.29x | 8.84x | 21.96x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 000597 Stock
- Valuation Northeast Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
















